Abdullah AlRajhi

Pharmacy Head, Hematology/Oncology Clinical Pharmacist @Oncoclinicas. Assistant Professor @Alfaisaluniv. يا رب انك تجمعنا بوالدي في جناتك

[AML Hub @AML_Hub]

CONGRESS | #EHA2026 | PRESENTATION

Yue Jin, Peking University People’s Hospital/Peking University Institute of Hematology, presents on the development and validation of a genetic–clinical prognostic algorithm for patients with R/R #AML undergoing allo-HSCT (derivation, n = 301; external validation, n = 297).

The model integrated OS-associated genetic factors, including FLT3-ITD (HR, 1.70; p = 0.007), mutated TP53 (HR, 2.47; p < 0.001), KMT2A rearrangement (HR, 1.95; p = 0.001), and complex karyotype (HR, 1.80; p = 0.008), with clinical factors including age at allo-HSCT ≥50 years (HR, 1.93; p < 0.001), CR/CRi with MRD+ before allo-HSCT (HR, 2.22; p < 0.001), active disease before allo-HSCT (HR, 3.26; p < 0.001), and donor age ≥60 years (HR, 2.57; p < 0.001). Based on these factors, patients were stratified into low-, intermediate-low-, intermediate-high-, and high-risk groups. For OS, the 1-, 2-, and 3-year AUCs were 0.826, 0.8156, and 0.819 in the internal validation cohort and 0.725, 0.756, and 0.789 in the external validation cohort, respectively; calibration aligned with observed mortality.

Follow our live feed for more updates: https://t.co/ekn3HdrQLM

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#leusm #MedicalCongress @PKU1898

[Graham Collins @graham74GC]

Many congratulations to @ABarrettHaem for delivering a fantastic presentation in the final data of the Avenue trial - avelumab prior to a RATHL approach in Hodgkin. #EHA2026

[Abdullah AlRajhi @3bdullahM]

@A_nassri Appreciate the kind words Dr. Abdulrahman! This effort inshallah will continued across major hematological diseases!

[JCO Global Oncology @JCOGO_ASCO]

Clinical Characteristics and Outcome of Diffuse Large B-Cell Lymphoma: Real World Data from Saudi Arabia.

Read the full article. https://t.co/ARvJhI70jM
#lymsm

[Abdullah AlRajhi @3bdullahM]

Happy to published out new article in JCO Global: Clinical Characteristics and Outcome of Diffuse Large B-Cell Lymphoma: Real-World Data From Saudi Arabia | JCO Global Oncology https://t.co/oVAfNsj9ID

[مشبب بن علي العسيري @masiri1111]

تكريم مستحق للغاية للزميل والاخ والصديق الدكتور فؤاد النجار استشاري صيدلة الاورام من جمعية صيدلة الاورام بجائزة الإنجاز مدى الحياة ..
الدكتور فؤاد بذل قصارى الجهد لوضع الأساس لهذا التخصص ودرب العشرات ولا يزال ..
كل الشكر والتقدير والاحترام لشخصه الكريم الذي يعمل بكل اخلاص والله ��قط يجزيه

[مشبب بن علي العسيري @masiri1111]

ينطلق صباح يوم الجمعة في الرياض المؤتمر الأول للجمعية السعودية لصيدل�� الأورام @SOPS_SA بقيادة الدكتورة المبدعة نوره الخضير @NaAlkhudair وزملائها وزميلاتها في الجمعية الفتية التي تسهم في تطوير وسلامة علاج السرطان بالأدوية الكيميائية والحيوية ومن المبهج تواجد هذه المجموعة الرائعة من الشبان والشابات الصيادلة المتخصصين في هذا التخصص الحديث نسبيا في علم الاورام ..

[SOPS @SOPS_SA]

📢 Registration is Now Open!

Registration for the SOPS Annual Conference 2026 is officially open
📅 April 3–4, 2026
📍 Riyadh, Crown Plaza RDC
🎓 14 CME Hours
Join oncology leaders, clinicians, and pharmacists for two days of scientific discussions, knowledge exchange, and networking.
✨ Featuring keynote remarks from national leaders in oncology and interactive expert panel discussions.
🔗 Register now: https://t.co/As9ZvRJfhR

We look forward to welcoming you!

[ALFONSO DUEÑAS GONZALEZ @duenas_gon28]

https://t.co/jDh1VNi2Jj

[JAMA Oncology @JAMAOnc]

ctDNA status may help identify which patients benefit from adjuvant celecoxib, supporting personalized treatment approaches in #ColonCancer. https://t.co/hrHKdnt4wy

[OncoClinic @oncoclinicgrksa]

نتشرف بخدمتكم

نقدّم رعاية متكاملة لمرضى الأورام ضمن بيئة إنسانية وبأعلى معايير العناية

للمواعيد والاستفسارات
8001240125
https://t.co/i3YDf2pSTl

Comprehensive patient-centered oncology care in a supportive environment

Appointments &amp; Inquiries
8001240125
https://t.co/i3YDf2pSTl

[Dana-Farber @DanaFarber]

We’re proud to announce a new strategic collaboration with OncoClinic to bring advanced and personalized oncology to Saudi Arabia. Learn more: https://t.co/4lu81s1b2Z

[Abdullah AlRajhi @3bdullahM]

@Shaimalzaidi احسن الله عزاكم وعظم الله اجركم
الله يغفر لها ويرحمها ويسكنها فسيح جناته

[SOPS @SOPS_SA]

📢
Don't miss our upcoming expert presentation on the local experience with CAR T-cell therapy in R/R B-Cell Lymphoma
Discover groundbreaking advancements and how this innovative treatment is transforming patient care right here in Saudi Arabia
#SOPSClub #HEMONC

[SOPS @SOPS_SA]

📢 Exciting news!
Our inaugural #SOPS Club session is coming next week!
Prepare for a deep dive into a critical topic with expert insights.
Keep an eye out for the big reveal ✨
#SOPSClub #HEMONC #Learning

[Graham Collins @graham74GC]

Ahmed et al - EBV &amp; cHL subtype in S1826 study
• EBV+ pts do much better with NAVD compared with BV-AVD (EBV- also do better but less marked)
• non-NS histology also benefited more from NAVD.
Biology is important!
#lymsm #18ICML #ICML25

[SOPS @SOPS_SA]

✨
Get ready for an exciting year with our SOPS club series!
Stay tuned for all the details and join us for some amazing experiences!

#SOPS_CLUB #LEARN #HEMONC

[SOPS @SOPS_SA]

نهنئكم بحلول #عيد_الأضحى_المبارك
نسأل الله أن يتقبّل من الحجاج حجهم و أن يتقبل منا ومنكم صالح الأعمال..
وكل عام وأنتم بخير

[SOPS @SOPS_SA]

📢 Announcement!

SOPS would like to extend the invitation to our first activity

- The INFINITE KNOWLEDGE: Clinical Pharmacists Chain of Events for Sharing Knowledge series

🎯 Intro to Clinical Trials in Oncology
🗓️ Sat, May 17
🕥 10:45 AM – 1:00 PM

Speaker: Dr. Riad El Fakih
Chair: Dr. Mohammed Al Zahrani

🔗 Interactive. Insightful. Unmissable!

#Oncology #ClinicalPharmacy #INFINITEKnowledge
#SOPS

[SOPS @SOPS_SA]

✨ يسرّنا الإعلان عن تشكيل مجلس الإدارة الجديد للجمعية السعودية للصيدلة الأورام (SOPS)�� بقيادة سعادة الدكتورة نورة الخضير
و الدكتورة عاتكة الحربي نائبًا للرئيس

وأعضاء مجلس الإدارة:
• د. محمد الناهض
• د. محمد النحيط
• د. أحمد العنزي
• د. ندى السحيباني
• د. عبدالله الراجحي

نتطلع إلى تحقيق إنجازات نوعية في مجال صيدلة الأورام وتعزيز دور الصيدلي في النظام الصحي في مملكتنا الحبيبة